Importantly, the WES analysis identified variants in CTCF, DNMT3A, DNMT1, EZH2 and SUV39H1, which have not been described in patients and families with FSHD before and, thus, they may represent novel candidate genetic modifiers for the disease. This evidence concerns the gene DNMT3A and Facioscapulohumeral dystrophy.